Navigation Links
Trovagene Announces Issuance of Broad MicroRNA Patent
Date:7/24/2013

SAN DIEGO, July 24, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced the issuance of US patent 8,486,626, "Methods of detecting cell-free miRNA in urine and blood." The patent pertains to the detection and quantitation of microRNA (miRNA) using a wide variety of technologies and platforms. MicroRNAs are known to play critical roles in cell development as well as a number of diseases, including cancer.

(Logo:  http://photos.prnewswire.com/prnh/20120620/LA28014LOGO)

"MicroRNA signatures are highly sensitive biomarkers with the potential to be used in a wide range of molecular diagnostic tests," states Mark Erlander, Ph.D., chief scientific officer of Trovagene.  "They have been shown to have varying expression levels across numerous pathological conditions including cancer, autoimmune and inflammatory diseases and cardiovascular diseases."

Despite their relatively recent discovery and characterization, several miRNA-based therapeutics have entered clinical trials, confirming their importance as critical regulators of human disease. "MicroRNAs hold the promise of yielding a new class of therapeutics in addition to current diagnostic uses," adds Erlander.

The new miRNA patent extends Trovagene's established intellectual property portfolio in the field of cell-free molecular diagnostics, which covers DNA and RNA fragments found in urine.  Trovagene already has proprietary methods around the isolation, detection and analysis of these cell-free nucleic acids from urine, a non-invasive and easy to obtain sample type.

"Cell-free nucleic acids, including microRNAs, are an integral part of our company's focus on cancer diagnostics. Our newly established patent position in microRNA detection in blood and urine will complement our proprietary capabilities to detect and quantify DNA mutations and genetic variations," said Antonius Schuh, Ph.D., chief executive officer of Trovagene. "We believe this technology promises to have a profound impact on the field of cancer diagnostics."

About Trovagene, Inc.
Headquartered in San Diego, California, Trovagene is leveraging its patented technology for the detection of cell-free DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that can be isolated and detected from urine. Trovagene has a strong intellectual property asset as it relates to cell-free DNA and RNA testing in urine. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement.  Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2012 and other periodic reports filed with the Securities and Exchange Commission.

Contact:

Trovagene, Inc.       

Stephen Zaniboni
Chief Financial Officer
Trovagene, Inc.
858-952-7594
szaniboni@trovagene.com


'/>"/>
SOURCE Trovagene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Trovagene, Inc., Announces Fourth Quarter and Year End 2012 Earnings
2. Trovagene Launches Urine-Based HPV Test
3. Trovagene Appoints Mark Erlander, Ph.D. as Chief Scientific Officer
4. Trovagene Announces Commercial Launch Timelines for HPV Carrier and Oncogene Mutation Tests
5. Trovagene to Introduce First Urine-Based Molecular Diagnostic Test for Transrenal Cancer Mutation Monitoring
6. Trovagene and Barretos Cancer Hospital, Brazil, to Evaluate Urine-Based HPV Assay as Potential Pap Smear Replacement
7. Trovagene Announces Closing of Private Placement of $3.76 Million from the Sale of Restricted Common Stock and Warrants
8. Dr. Paul Billings joins Trovagenes Scientific Advisory Board
9. Trovagene, Inc., Announces Third Quarter and Year to Date Earnings, Provides Milestone Update
10. Trovagene and Strand Life Sciences Agree to Validate and Commercialize Urine-Based HPV Test in India and South Asia
11. Trovagene, Inc. Announces Second Quarter and Year to Date Earnings, Provides Milestone Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... 2016 Intec Pharma Ltd. (NASDAQ: ... company, today announced the appointment of Pnina Strauss-Levy ... "Ms. Strauss-Levy has 15 years of experience in ... outstanding track record, having supported the advancement of several ... in the United States and ...
(Date:5/3/2016)... PUNE, India , May 3, 2016 /PRNewswire/ ... Market 2016 Research Report provides a basic overview ... manufacturing technology, post which the surgical mesh report ... the market. Complete report on Surgical ... company profiles and 98 tables and figures is ...
(Date:5/2/2016)... May 2, 2016 Kalorama Information noted the ... Records) market in a recent white paper.  The healthcare ... physician usage, a growing market are among the top ... Kalorama,s report EMR 2016: The Market for ... seventh complete study of the EMR industry, and the ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... 04, 2016 , ... IsoComforter, Inc., one of the Nations ... newly improved Iso-Hip Wrap. The newly designed hip wrap has been specifically ... enables the patient to enjoy the benefits of cold therapy while resting, sitting, ...
(Date:5/4/2016)... ... ... A new collaboration will give more researchers access to the largest and ... leader SAS will provide researchers worldwide with data management and analytics tools to explore ... , The DCRI and SAS share the goal of greater transparency and openness in ...
(Date:5/4/2016)... ... May 04, 2016 , ... Slepkow Slepkow & ... one of the top website design companies to create a state of the ... to the law firm's main practice areas. These practice areas include: real estate, ...
(Date:5/4/2016)... ... , ... Francesca Loparco, Co-Founder of Queen City Dream Cars, an exotic car ... procedure at Christenbury Eye Center. The entrepreneur struggled with her computer, riding horses ... day as her in-office consultation and eye exam. Francesca’s eyesight was restored to 20/20 ...
(Date:5/4/2016)... ... 2016 , ... Advanced Spine & Sport Medical Rehabilitation Center, which is renowned ... a free seminar on stem cell injections. The seminar is scheduled for Wednesday, May ... Telephone Road, Suite 110, Ventura, CA. There are only 10 seats available. , ...
Breaking Medicine News(10 mins):